Bio Rad Labs Inc Stock Price, News & Analysis

Bio-Rad Laboratories (NYSE: BIO, BIO.B), a leader in life science research and clinical diagnostics, announced that CEO Norman Schwartz and CFO Roop K. Lakkaraju will participate in a fireside chat at the 2025 RBC Capital Markets Global Healthcare Conference. The event is scheduled for May 21, 2025, at 1:35 PM ET. Investors can access the live webcast and replay through Bio-Rad's Investor Relations website section at bio-rad.com.

Bio-Rad Laboratories reported its Q1 2025 financial results, showing a decline in performance. Total net sales decreased 4.2% to $585.4 million compared to Q1 2024. The Life Science segment saw a 5.4% decline to $228.6 million, while Clinical Diagnostics dropped 3.2% to $356.8 million. GAAP net income fell significantly to $64.0 million ($2.29 per share) from $383.9 million ($13.45 per share) in Q1 2024. However, non-GAAP net income improved to $71.0 million ($2.54 per share) from $65.3 million. Due to market uncertainty, Bio-Rad revised its 2025 outlook, now expecting non-GAAP revenue between -1.0% decline to 1.5% growth, down from previous 1.5-3.5% growth forecast. Operating margin guidance was also reduced to 10.0-12.0% from 13.0-13.5%.

Bio-Rad Laboratories (NYSE: BIO) has announced it will release its first quarter 2025 financial results on Thursday, May 1, 2025, after market close. The company, a global leader in life science research and clinical diagnostics products, will host a conference call at 2:30 PM Pacific Time (5:30 PM Eastern Time) to discuss the results.

Interested participants can join the call by dialing (800) 715-9871 within the U.S. or (646) 307-1963 internationally, using access code: 9562470. A live webcast will be available in the Investor Relations section of Bio-Rad's website, with the replay accessible for up to one year.

Bio-Rad Laboratories (NYSE: BIO) reported Q4 2024 financial results with total net sales of $667.5 million, down 2.0% from Q4 2023. The Life Science segment saw a 5.5% decline to $275.0 million, while Clinical Diagnostics segment increased 0.9% to $392.5 million.

For full-year 2024, revenue decreased 3.9% to $2,566.5 million. The company reported a net loss of $1,844.2 million ($65.36 per share), largely due to changes in fair market value of Sartorius AG investment. Non-GAAP net income was $291.1 million ($10.31 per share).

Bio-Rad announced plans to acquire Stilla Technologies, expecting to close by Q3 2025. The company projects 2025 non-GAAP currency-neutral revenue growth of 1.5-3.5% and operating margin of 13.0-13.5%.

Bio-Rad Laboratories (NYSE: BIO) has announced a binding offer to acquire Stilla Technologies, a developer of next-generation digital PCR solutions. The acquisition, expected to close by the end of Q3 2025, aims to complement Bio-Rad's existing digital PCR portfolio.

Stilla, operating in France and the U.S., develops the Nio® family of all-in-one digital PCR systems, which supports genetic testing across multiple applications including liquid biopsy, oncology diagnostics, cell and gene therapy, organ transplant testing, infectious diseases, and food and environmental testing.

The integration would enhance Bio-Rad's capabilities in applied research and clinical diagnostics, particularly in areas requiring higher automation and throughput. Together with Bio-Rad's planned launch of the QX Continuum™ system, the combined platforms would serve a full range of digital PCR applications in genomics research and applied science.

Bio-Rad Laboratories (NYSE: BIO and BIO.B) has announced it will release its fourth quarter and full year 2024 financial results on Thursday, February 13, 2025, after market close. The company will host a conference call at 2 PM Pacific Time (5 PM Eastern Time) to discuss the results. Investors can join via phone by dialing (800) 715-9871 (U.S.) or (646) 307-1963 (international) using access code 9562470. A live webcast will be available in the Investor Relations section of Bio-Rad's website, with the replay accessible for up to one year.

Geneoscopy has successfully closed a $105 million Series C funding round, led by Bio-Rad Laboratories (NYSE: BIO). The funding will support the launch of ColoSense®, a non-invasive colorectal cancer screening test, and advance diagnostic innovations for inflammatory bowel disease.

The investment round included participation from notable investors including Petrichor, Labcorp, Morningside Ventures, and others. Geneoscopy's technology combines RNA isolation from stool samples with Bio-Rad's Droplet Digital™ PCR technology for effective cancer screening. Through a partnership with Labcorp, ColoSense will be made widely available to healthcare providers.

This funding follows FDA approval of ColoSense and aims to address the rising incidence of colorectal cancer, particularly among people under 50. The test offers a non-invasive alternative to traditional colonoscopies, potentially increasing screening accessibility for millions of eligible individuals who currently avoid testing.

Bio-Rad Laboratories (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, has announced its participation in J.P. Morgan's 43rd Annual Healthcare Conference. The company's leadership team, including CEO Norman Schwartz, COO Jon DiVincenzo, and CFO Roop K. Lakkaraju, will conduct one-on-one meetings with analysts and investors during the conference, which is scheduled to take place in San Francisco, CA from January 13-16, 2025.

Bio-Rad Laboratories (NYSE: BIO and BIO.B) has announced its participation in Citi's 2024 Global Healthcare Conference in Miami, FL, scheduled for December 3-5, 2024. The company's CEO Norman Schwartz and CFO Roop K. Lakkaraju will conduct one-on-one meetings with analysts and investors during the event. Bio-Rad, recognized as a global leader in life science research and clinical diagnostics products, aims to engage directly with the investment community through these meetings.